NDA 018701 · Janssen Pharms
Haldol
Haloperidol Decanoate · Injection
DiscontinuedLast checked: Nov 20, 2026Latest source record: Oct 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Jan 14, 1986
Approved uses
1
Original approval plus efficacy supplements
Registered trials
170
51 Phase 3, 4 recruiting
FAERS reports
1,743
1,546 serious, 153 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with...
What it is approved for
From the label in effect Feb 19, 2025.
INDICATIONS AND USAGE Haloperidol decanoate 50 and Haloperidol decanoate 100 are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 14, 1986 Original approval · Type 2 - New Active Ingredient
2 products under this application
- HALDOL · HALOPERIDOL DECANOATE EQ 50MG BASE/ML · INJECTABLE, INJECTION · Discontinued · TE AO
- HALDOL · HALOPERIDOL DECANOATE EQ 100MG BASE/ML · INJECTABLE, INJECTION · Discontinued · TE AO
Clinical trials
Interventional ClinicalTrials.gov studies with "Haloperidol Decanoate" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Metabolic Profile and Anthropometric Changes in SchizophreniaPivotal-lookingCompleted
Central Institute of Psychiatry, Ranchi, IndiaAcademic, hospital or other
NCT00534183 · 2,006 participants · Start Jun 2006
Drug: Olanzapine; Risperidone and 1 more · For: Metabolic Syndrome; Diabetes; Obesity
Sites: Ranchi, India
- pRophylactic halopEriDol Use for Delirium in iCu patiEnts With a High Risk for DeliriumPivotal-lookingCompleted
Radboud University Medical CenterAcademic, hospital or other
NCT01785290 · 1,800 participants · Start Jun 2013 · Primary completion Dec 2016
Drug: Haloperidol 1 mg/q8h; Haloperidol 2 mg/q8h and 1 more · For: Delirium
Sites: Nijmegen, Netherlands
- A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic SchizophreniaPivotal-lookingCompleted
Janssen, LPJohnson & Johnson (Janssen) (JNJ)
NCT00249119 · 1,579 participants
Drug: risperidone · For: Schizophrenia; Psychotic Disorder
- PROfylactic Haloperidol in Patients Defined as High Risk for DElirium With Delirium Risk mOdelPivotal-lookingStatus unknown
Zuyderland Medisch CentrumAcademic, hospital or other
NCT03199950 · 1,366 participants (planned) · Start Jun 23, 2017 · Primary completion Nov 23, 2018
Drug: Haloperidol; Placebo Oral Tablet · For: Delirium
Sites: Sittard, Netherlands
- Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01594749 · 1,015 participants · Start Sep 24, 2012 · Primary completion Nov 3, 2014
Drug: Fosaprepitant dimeglumine; Fosaprepitant Placebo and 5 more · For: Chemotherapy-Induced Nausea and Vomiting (CINV)
- The Danish Out-of-Hospital Cardiac Arrest StudyPivotal-lookingActive, not recruiting
Christian HassagerAcademic, hospital or other
NCT05895838 · 1,000 participants (planned) · Start Jun 16, 2023 · Primary completion Sep 2027
Drug: Dexamethasone; Olanzapine · For: Out-Of-Hospital Cardiac Arrest; Post-Cardiac Arrest Syndrome
Sites: Copenhagen, Denmark; Aalborg, Denmark; Aarhus, Denmark · 5 sites in all
- Agents Intervening Against Delirium in Intensive Care UnitPivotal-lookingStatus unknown
Zealand University HospitalAcademic, hospital or other
NCT03392376 · 1,000 participants (planned) · Start Jun 13, 2018 · Primary completion Jul 9, 2022
Drug: Haloperidol Injection · For: Delirium
Sites: Aabenraa, Denmark; Aalborg, Denmark; Copenhagen, Denmark · 16 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- weight increased241
- drug ineffective168
- extrapyramidal disorder147
- off label use134
- akathisia127
- drug interaction116
- suicide attempt107
- leukopenia97
- toxicity to various agents97
- neuroleptic malignant syndrome96
- product use in unapproved indication84
- treatment noncompliance73
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 30 |
| 2005 | 34 |
| 2006 | 42 |
| 2007 | 190 |
| 2008 | 19 |
| 2009 | 65 |
| 2010 | 31 |
| 2011 | 26 |
| 2012 | 41 |
| 2013 | 50 |
| 2014 | 59 |
| 2015 | 76 |
| 2016 | 49 |
| 2017 | 64 |
| 2018 | 45 |
| 2019 | 87 |
| 2020 | 77 |
| 2021 | 101 |
| 2022 | 134 |
| 2023 | 165 |
| 2024 | 131 |
| 2025 | 146 |
| 2026 | 81 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Haldol* (Haloperidol Lactate*) · HCPCS J1630
2024 spending
$550
Beneficiaries
98
175 claims
Per beneficiary
$6
2024 ASP limit $1.22 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $498 |
| 2021 | $536 |
| 2022 | $548 |
| 2023 | $625 |
| 2024 | $550 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Schizophrenia.
Barry SJ, Gaughan TM, Hunter R · BMJ Clin Evid 2012 · Systematic Review
- Antipsychotics for delirium.
Lonergan E, Britton AM, Luxenberg J, et al. · Cochrane Database Syst Rev 2007 · Meta-Analysis, Systematic Review
- Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.
Stroup TS, Bareis NA, Rosenheck RA, et al. · J Clin Psychiatry 2018 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Bromperidol decanoate (depot) for schizophrenia.
Purgato M, Adams CE · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Depot bromperidol decanoate for schizophrenia.
Wong D, Adams CE, David A, et al. · Cochrane Database Syst Rev 2004 · Systematic Review
- A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G, Annable L, Campbell W · J Clin Psychopharmacol 1989 · Clinical Trial, Comparative Study
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.